Petros Pharmaceuticals, Inc. (PTPI)
NASDAQ: PTPI · Real-Time Price · USD
0.0579
+0.0039 (7.22%)
At close: Apr 28, 2025, 4:00 PM
0.0626
+0.0047 (8.12%)
Pre-market: Apr 29, 2025, 7:02 AM EDT

Petros Pharmaceuticals Stock Forecast

Stock Price Forecast

There is currently no analyst price target forecast available for Petros Pharmaceuticals.

Analyst Consensus: n/a
Target Low Average Median High
Price n/a n/a n/a n/a
Change n/a n/a n/a n/a

Analyst Ratings

There are currently no analyst ratings available for Petros Pharmaceuticals.

Recommendation Trends

Rating Dec '23
Strong Buy 0
Buy 0
Hold 0
Sell 0
Strong Sell 0
Total 0

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
Maxim Group
Maxim Group
Strong Buy
Initiates
$4
Strong Buy Initiates $4 +6,808.46% Dec 8, 2023
More Analyst Ratings

Financial Forecast

Revenue This Year
5.59M
from 5.11M
Increased by 9.25%
Revenue Next Year
5.56M
from 5.59M
Decreased by -0.41%
EPS This Year
-1.11
from -3.34
EPS Next Year
-1.12
from -1.11
Fiscal Year FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026 FY 2027
Period Ending Dec 31, 2020 Dec 31, 2021 Dec 31, 2022 Dec 31, 2023 Dec 31, 2024 Dec 31, 2025 Dec 31, 2026 Dec 31, 2027
Revenue
9.56M7.81M5.99M5.82M5.11M5.59M5.56M11.28M
Revenue Growth
-38.63%-18.29%-23.29%-2.83%-12.20%9.25%-0.41%102.75%
EPS
-38.55-8.25-9.68-6.35-3.34-1.11-1.12-0.71
EPS Growth
--------
Forward PE
--------
No. Analysts
-----333
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 20252026202720282029
High 5.7M 5.7M 11.6M
Avg 5.6M 5.6M 11.3M
Low 5.4M 5.3M 10.8M

Revenue Growth

Revenue Growth 20252026202720282029
High
12.5%
2.5%
108.7%
Avg
9.3%
-0.4%
102.8%
Low
5.0%
-4.3%
94.8%

EPS Forecast

EPS 20252026202720282029
High -1.14 -1.16 -0.74
Avg -1.11 -1.12 -0.71
Low -1.07 -1.08 -0.69

EPS Growth

EPS Growth 20252026202720282029
High - - -
Avg - - -
Low - - -
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.